Iteos Therapeutics Inc. is a biopharmaceutical company dedicated to advancing the development of innovative cancer therapies
The company focuses on discovering and developing novel immune-oncology treatments that harness the body's immune system to target and fight cancer more effectively. With a strong emphasis on research and development, Iteos aims to create breakthrough medicines that can improve outcomes for patients living with various types of cancers, while also exploring unique mechanisms of action to address unmet medical needs in the oncology space.
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments that defied the trend by moving lower.
Gainers SciSparc Ltd. (NASDAQSPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for PD-L1-high
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Wednesday. The Dow traded up 0.51% to 34,462.61 while the NASDAQ rose 1.60% to 13,722.24. The S&P 500, also rose, gaining, 1.08% to 4,435.09.
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Wednesday. The Dow traded up 0.40% to 34,425.29 while the NASDAQ rose 1.40% to 13,694.79. The S&P 500, also rose, gaining, 0.88% to 4,426.35.
